EVAX Evaxion A/S
Price Chart
Executive Summary
Evaxion reported Q1 2026 results with net loss widening to $3.6M from $1.6M due to lower financial income, while operating expenses remained roughly flat. Cash of $18.4M provides runway into H2 2027. R&D progress includes positive immunogenicity data for EVX-01 (86% target recognition) and completion of phase 2 extension, but no new partnerships or near-term catalysts were announced.
Actionable Insight
Monitor for partnership announcements and EVX-01 three-year data in H2 2026. Current cash runway into H2 2027 suggests no near-term financing urgency, but the widened net loss and pre-revenue status imply eventual capital needs.
Key Facts
- Net loss Q1 2026: $3.6M vs $1.6M Q1 2025 (increase due to lower financial income)
- Operating loss slightly improved: -$3.819M vs -$3.868M
- Cash and equivalents: $18.4M as of March 31, 2026 (down from $23.2M at Dec 31, 2025)
- Cash runway confirmed into second half of 2027
- No revenue; zero revenue in both periods
- 86% vaccine target recognition rate reported for EVX-01 from AACR data
- Phase 2 extension for EVX-01 completed; three-year data expected H2 2026
- New polio vaccine design concepts presented from Gates Foundation collaboration
- Promoted Chief Scientific/COO and added new Board member with dealmaking experience
Financial Impact
Net loss increased $2.0M YoY due to $2.2M decline in financial income; cash burn ~$3.6M/quarter
Risk Factors
- No near-term revenue and increasing net loss
- Need for additional capital beyond current runway
- Clinical trial risks for EVX-01 and pipeline candidates
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003114 |
| Document: f6k_050726.htm | 0001171843-26-003114 |
| Document: 0001171843-26-003114-index-headers.html | 0001171843-26-003114 |
| Document: 0001171843-26-003114-index.html | 0001171843-26-003114 |
| Document: 0001171843-26-003114.txt | 0001171843-26-003114 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 12, 2026
28d ago
|
6-K
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.73 (−10.55%) |
|
May 12, 2026
28d ago
|
Press Release
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.73 (−10.55%) |
|
May 7, 2026
4w ago
|
6-K
| $4.07 $4.16 | ▲ +2.21% | ▲ +0.71% | $3.73 (−8.35%) |
|
May 4, 2026
5w ago
|
Press Release
| $4.57 $4.23 | ▼ −7.55% | ▼ −10.49% | $3.73 (−18.38%) |
|
Apr 27, 2026
6w ago
|
6-K
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.73 (−10.77%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.73 (−10.77%) |
|
Apr 22, 2026
6w ago
|
6-K
| $4.27 $4.27 | · 0.00% | ▼ −0.05% | $3.73 (−12.65%) |
|
Apr 17, 2026
7w ago
|
6-K
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $3.73 (−16.18%) |
|
Apr 17, 2026
7w ago
|
6-K
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $3.73 (−16.18%) |
|
Apr 17, 2026
7w ago
|
Press Release
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $3.73 (−16.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access